CliffBio
small molecule

ADHANSIA XR

METHYLPHENIDATE HYDROCHLORIDE

Loss of exclusivityNovember 2038latest FDA-listed patent expiry
CompanyKNOA →View the full company profile on CliffBio

Drug detail

Brand nameADHANSIA XR
Active ingredientMETHYLPHENIDATE HYDROCHLORIDE
Strength35MG
Dosage formCAPSULE, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalFebruary 2019
Marketing statusDISCN

Listed patents

PatentExpiresType
10722473November 2038use U-2357
10512613October 2035use U-2357
10449159October 2035use U-2357
10500162October 2035use U-2357
10568841October 2035product
10292939October 2035product
10688060October 2035product
10507186October 2035product
10292938October 2035product
9974752October 2035product
10111839October 2035use U-2357
10512612October 2035product

More from KNOA

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ADHANSIA XR patent cliff — loss of exclusivity November 2038 | CliffBio